Vaccine News and Research

Latest Vaccine News and Research

Swine flu news round-up

The German government is looking to sell over 2 million leftover doses of the H1N1 (swine flu) vaccine, the country's health minister said Monday, Agence France-Presse reports. "A health ministry senior official in the state of Thuringia, Hartmut Schubert, said that the vaccines could even be donated and that there had been requests from Afghanistan and Eastern European countries including Ukraine," the news service adds (12/7).

8 Dec 2009

ADVocacy for IMmunization program receives a three-year grant from the Bill & Melinda Gates Foundation

The Agence de Médecine Préventive (AMP) has received a three-year grant from the Bill & Melinda Gates Foundation to implement a program to support immunization advocacy in West Africa.

8 Dec 2009

Interim data from Geron's GRNVAC1 phase II trial for AML presented

Geron Corporation today announced the presentation of interim data from its phase II trial of GRNVAC1, an autologous dendritic cell vaccine targeting telomerase, in patients with acute myelogenous leukemia (AML) at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

8 Dec 2009

BARDA cancels PharmAthene's RFP for Recombinant Protective Antigen Anthrax Vaccine

PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that the Department of Health and Human Services Biomedical Research and Development Authority (BARDA) has canceled its request for proposal (RFP) for Recombinant Protective Antigen Anthrax Vaccine for the Strategic National Stockpile (RFP BARDA 08-15).

8 Dec 2009

Department of Health reminds at-risk Pennsylvanians to receive H1N1 vaccination

The federal Centers for Disease Control and Prevention, or CDC, has allocated a total of 2,940,300 doses of H1N1 flu vaccine to Pennsylvania to date, the state Department of Health said today.

8 Dec 2009

Enrollment of patients for Phase I/IIa clinical study of Interleukin-7 commenced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in its Phase I/IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in combination with standard antiviral treatment and vaccination in HBeAg-negative chronic hepatitis B-infected (HBV) patients.

8 Dec 2009

LCA-GA praises Senators' support in establishing comprehensive program for lung cancer

Today, Lung Cancer Alliance-Georgia (LCA-GA) acknowledged Senators Saxby Chambliss (R-GA) and Johnny Isakson (R-GA) for their leadership and support in establishing the first ever multi-agency, comprehensive program targeted at lung cancer.

8 Dec 2009

Travelers may risk both health and travel insurance coverage by not getting vaccinated

With tens of thousands of people set to travel abroad over the Christmas period, AA Travel Insurance are today urging travellers to be properly vaccinated before travelling.

8 Dec 2009

New data from NanoBio's nanoemulsion-based adjuvant platform to be presented

NanoBio Corporation announced today that its CEO and Founder, James R. Baker, Jr., M.D., will present new data from studies of its nanoemulsion-based adjuvant platform during the World Influenza Congress, taking place from December 7-9, 2009 in Brussels, Belgium.

8 Dec 2009

Human blood stem cells can be engineered to kill HIV-infected cells, find researchers

Researchers from the UCLA AIDS Institute and colleagues have for the first time demonstrated that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells — a process that potentially could be used against a range of chronic viral diseases.

8 Dec 2009

La Jolla Pharmaceutical enters into definitive merger agreement with Adamis Pharmaceuticals

La Jolla Pharmaceutical Company (“La Jolla”) today announced that it entered into a definitive merger agreement with Adamis Pharmaceuticals Corporation (“Adamis”) on December 4, 2009.

8 Dec 2009

H1N1 virus causes more life-threatening complications than seasonal flu

Infection with the H1N1 virus, or swine flu, causes more life-threatening complications than seasonal flu in children with sickle cell disease, according to research from Johns Hopkins Children's Center.

8 Dec 2009

HHS joins with Ad Council to launch new nationwide PSA campaign

HHS Secretary Kathleen Sebelius announced today that the U.S. Department of Health and Human Services (HHS) is joining with the Ad Council to launch a new nationwide public service advertising (PSA) campaign called “Together We Can All Fight the Flu.”

7 Dec 2009

Millipore introduces new handheld, automated cell counter

Millipore Corporation, a leading provider of technologies, tools and services for the global life sciences industry, today introduced Scepter™, the industry’s first handheld, automated cell counter, at the American Society of Cell Biology Annual Meeting in San Diego.

7 Dec 2009

Adamis Pharmaceuticals to acquire La Jolla Pharmaceutical Company

Adamis Pharmaceuticals Corporation (OTCBB: ADMP), announced today that it has entered into a definitive merger agreement providing for the acquisition of La Jolla Pharmaceutical Company by Adamis.

7 Dec 2009

H1N1 reported in Gaza, Southern Sudan

Two women have become the first to die from H1N1 (swine flu) in Gaza, health officials said Monday, Agence France-Presse/Inquirer.net reports. The announcement came after five patients were confirmed to have H1N1 - the first cases in the region.

7 Dec 2009

PharmAthene presents Protexia clinical trial results at PHEMCE conference

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced Phase I clinical trial results for Protexia, a pegylated recombinant version of human butyrylcholinesterase (rBChE), which has been shown to be effective in animal models in preventing toxicity from exposure to chemical nerve agents.

7 Dec 2009

CDC announces the start of National Influenza Vaccination Week

Today the Centers for Disease Control and Prevention (CDC) announced the start of National Influenza Vaccination Week. While the week was designed to highlight the importance of flu vaccinations, it also brings to light the importance of taking additional steps to keep you and your family healthy during the peak cold and flu season of December, January and beyond.

7 Dec 2009

Phase I/II clinical trial of Multimeric-001 Universal Flu Vaccine successful

BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company at the forefront of the development of a Universal Influenza Vaccine, announced the success of the Phase I/II clinical trial of the Company's Multimeric-001 Universal Flu Vaccine, in trials conducted at the Sourasky Medical Center in Tel Aviv, Israel.

7 Dec 2009

Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris

Alexion Pharmaceuticals, Inc. today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris® (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).

7 Dec 2009